Drs Gail Roboz and Roland Walter discuss measurable residual disease and relapse in patients with acute myeloid leukemia.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/964539). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Bone Marrow Biopsy https://emedicine.medscape.com/article/197802-workup

Stem Cell Transplant https://emedicine.medscape.com/article/208954-overview

Donor Lymphocyte Infusions https://pubmed.ncbi.nlm.nih.gov/11941577/

Hypomethylating Agents https://emedicine.medscape.com/article/197802-treatment

FLT3, IDH2 https://emedicine.medscape.com/article/197802-workup#c9

Measurable Residual Disease https://decisionpoint.medscape.com/oncology/viewarticle/928279

2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document From the European LeukemiaNet MRD Working Party https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718623/

Measurable Residual Disease as a Biomarker in Acute Myeloid Leukemia: Theoretical and Practical Considerations https://www.nature.com/articles/s41375-021-01230-4

Core Binding Factor https://www.medscape.com/viewarticle/408452_4

Minimal Residual Disease Eradication With Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779853/

Minimal Residual Disease Monitoring by Quantitative RT-PCR in Core Binding Factor AML Allows Risk Stratification and Predicts Relapse: Results of the United Kingdom MRC AML-15 Trial https://ashpublications.org/blood/article/120/14/2826/30510/Minimal-residual-disease-monitoring-by

MRD-Directed Risk Stratification Treatment May Improve Outcomes of t(8;21) AML in the First Complete Remission: Results From the AML05 Multicenter Trial https://pubmed.ncbi.nlm.nih.gov/23535063/

Drs Gail Roboz and Courtney DiNardo discuss methods of treating older patients with acute myeloid leukemia and managing unique toxicities.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/964537). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Acute Myeloid Leukemia https://emedicine.medscape.com/article/197802-overview

Cytarabine https://reference.medscape.com/drug/cytosar-u-depocyt-cytarabine-342089

Mylotarg (gemtuzumab ozogamicin) https://reference.medscape.com/drug/mylotarg-gemtuzumab-1000186

A Phase 3 Trial of Azacitidine Versus a Semi-Intensive Fludarabine and Cytarabine Schedule in Older Patients With Untreated Acute Myeloid Leukemia https://pubmed.ncbi.nlm.nih.gov/33626197/

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia https://www.nejm.org/doi/full/10.1056/NEJMoa2012971

Ferrara Criteria https://decisionpoint.medscape.com/oncology/viewarticle/928810

Hydrea https://reference.medscape.com/drug/droxia-siklos-hydroxyurea-342100

Mucositis https://emedicine.medscape.com/article/1079570-overview

Azacytidine https://reference.medscape.com/drug/onureg-vidaza-azacitidine-342263

Decitabine https://reference.medscape.com/drug/dacogen-decitabine-342091

Venetoclax https://reference.medscape.com/drug/venclexta-venetoclax-1000078

Hydroxycarbamide in Combination With Azacitidine or Decitabine Is Antagonistic on DNA Methylation Inhibition https://pubmed.ncbi.nlm.nih.gov/17686055/

Drs Gail Roboz and Alexander Perl discuss adverse-risk acute myeloid leukemia.

Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/964535). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study https://ascopubs.org/doi/10.1200/JCO.2012.45.9628

Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291965/

The Presence of a FLT3 Internal Tandem Duplication in Patients With Acute Myeloid Leukemia (AML) Adds Important Prognostic Information to Cytogenetic Risk Group and Response to the First Cycle of Chemotherapy: Analysis of 854 Patients From the United Kingdom Medical Research Council AML 10 and 12 trials https://www.sciencedirect.com/science/article/pii/S0006497120609351?via%3Dihub

Diagnostic and Therapeutic Pitfalls in NPM1-Mutated AML: Notes From the Field https://www.nature.com/articles/s41375-021-01222-4

Prognostic Impact of DNMT3A Mutation in Acute Myeloid Leukemia With Mutated NPM1 https://www.sciencedirect.com/science/article/pii/S2473952921005425

Midostaurin Plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754190/pdf/nihms901401.pdf

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First) https://clinicaltrials.gov/ct2/show/NCT02668653

A Review of FLT3 Inhibitors in Acute Myeloid Leukemia https://www.sciencedirect.com/science/article/abs/pii/S0268960X21001119?via%3Dihub

Abstract 591: Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16) https://ash.confex.com/ash/2020/webprogram/Paper137334.html

AC220 Is a Uniquely Potent and Selective Inhibitor of FLT3 for the Treatment of Acute Myeloid Leukemia (AML) https://news.unboundmedicine.com/medline/citation/19654408/AC220_is_a_uniquely_potent_and_selective_inhibitor_of_FLT3_for_the_treatment_of_acute_myeloid_leukemia__AML__

Daiichi Waits on FDA as AML Drug Quizartinib Approved in Japan https://pharmaphorum.com/news/daiichi-waits-on-fda-as-aml-drug-quizartinib-approved-in-japan/

FDA Declines to Approve Quizartinib for FLT3-Mutated Acute Myeloid Leukemia https://ashpublications.org/ashclinicalnews/news/4584/FDA-Declines-to-Approve-Quizartinib-for-FLT3

Safety and Preliminary Efficacy of Venetoclax With Decitabine or Azacitidine in Elderly Patients With Previously Untreated Acute Myeloid Leukaemia: A Non-randomised, Open-Label, Phase 1b Study https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30010-X/fulltext

Triplet Therapy With Venetoclax, FLT3 Inhibitor and Decitabine for FLT3-Mutated Acute Myeloid Leukemia https://www.nature.com/articles/s41408-021-00410-w

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients With Acute Myeloid Leukemia and IDH1/2 Mutations https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-21-3467/677977/Impact-of-Venetoclax-and-Azacitidine-in-Treatment

Abstract 32: Comparing Outcomes Between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia https://ash.confex.com/ash/2021/webprogram/Paper145947.html

Abstract 795: Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia https://ash.confex.com/ash/2021/webprogram/Paper149158.html